Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI technique could sharpen detection of active MS lesions

NCT ID NCT03268239

Diagnosis Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested two different MRI sequences to see which one better detects active inflammatory lesions in the brains of people with multiple sclerosis (MS). 180 adults with known central nervous system inflammatory disease who needed an MRI after a recent clinical event took part. The goal was to compare a 3D gradient-echo sequence against a 3D turbo-spin-echo sequence after contrast injection, to find the most sensitive method for spotting active lesions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to more accurate MRI detection of active MS lesions, helping doctors better diagnose and monitor the disease.
What could go wrong
This is a completed imaging study, not a treatment trial. The results may not change current practice if the new sequences do not prove significantly better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

180 people

The number who actually took part.

Started

Aug 2017

Finished

Apr 2021

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Equal or more than 18 years of age * Able to provide written informed consent. * Known central nervous system inflammatory disease * Magnetic Resonance exam needed for evaluation after a clinical event in the last 3 weeks Exclusion Criteria: * Current treatment with dimethylfumarate (Tecfidera®), natalizumab (Tysabri®) or fingolimod (Gilenya®) * Contraindications either to 3 Tesla Magnetic Resonance Imaging (e.g. certain metallic and electronic implants, claustrophobia) or IV gadolinium contrast (allergy, pregnancy, breast-feeding, renal insufficiency).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain disorder central nervous system disorder demyelinating disease multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN Central nervous system Demyelinating diseases Magnetic resonance imaging Multiple sclerosis

Contacts and locations

Locations

  • Fondation Ophtalmologique A. de Rothschild

    Paris, France, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.